NCT02486055View on ClinicalTrials.gov

A Safety Study of Orally Administered BPM31510 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Healthy
Interventions
DRUG

BPM31510 Oral Nanosuspension 4%

Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)

Trial Locations (1)

07724

Clinilabs, Inc., Eatontown

All Listed Sponsors
lead

BPGbio

INDUSTRY

NCT02486055 - A Safety Study of Orally Administered BPM31510 in Healthy Subjects | Biotech Hunter | Biotech Hunter